MAIA Biotechnology (MAIA) Retained Earnings (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Retained Earnings of $143.8 million for Q1 2026, up 376975.96% year-over-year from N/an in Q1 2025, and up 286388.57% quarter-over-quarter from -$50228.0 in Q4 2025.
MAIA Biotechnology (MAIA) Retained Earnings (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Retained Earnings for 6 consecutive years, with $143.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 376975.96% year-over-year to $143.8 million; the TTM figure through Mar 2026 stood at $143.8 million (up 376975.96% YoY), while the FY2025 annual figure was -$50228.0, down 64.06% from the prior year.
- Retained Earnings improved to $143.8 million in Q1 2026 per MAIA's latest filing, from -$50228.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $143.8 million in Q1 2026 and bottomed at -$106.0 million in Q3 2025.
- Historically, Retained Earnings has averaged $9.5 million across 5 years, with a median of -$27968.0 in 2023.
- Annual changes were most pronounced in 2024 — Retained Earnings slumped 238.25% — and 2026, when it soared 376975.96%.
- MAIA Biotechnology's Retained Earnings stood at $52.7 million in 2022, then slumped by 100.03% to -$16260.0 in 2023, then tumbled by 88.28% to -$30615.0 in 2024, then slumped by 64.06% to -$50228.0 in 2025, then jumped by 286388.57% to $143.8 million in 2026.
- Business Quant data shows MAIA's Retained Earnings at $143.8 million in Q1 2026, -$50228.0 in Q4 2025, and -$106.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | 144.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144.65 Mn |
| Mar 31, 2026 | 143.80 Mn |
| Dec 31, 2025 | -50,228.00 |
| Sep 30, 2025 | -106.00 Mn |
| Jun 30, 2025 | -30,028.00 |
| Mar 31, 2025 | -38,155.00 |
| Dec 31, 2024 | -30,615.00 |
| Sep 30, 2024 | -83.66 Mn |
| Jun 30, 2024 | -22,178.00 |
| Mar 31, 2024 | 66.31 Mn |
| Dec 31, 2023 | -16,260.00 |
| Sep 30, 2023 | 60.51 Mn |
| Jun 30, 2023 | -25,908.00 |
| Mar 31, 2023 | 53.43 Mn |
| Dec 31, 2022 | 52.73 Mn |
| Sep 30, 2022 | -51,646.00 |
| Jun 30, 2022 | -35.16 Mn |
| Dec 31, 2021 | 37.62 Mn |